Pharma's Medical Liaisons: From KOLs To Outcomes And Virtual Options
Executive Summary
Compliance issues, boundaries of off-label discussions and an enhanced emphasis on patient health outcomes are shaping how medical science liaisons (MSLs) engage with existing and emerging stakeholders. Scrip spoke to senior executives from UCB, GlaxoSmithKline, Novartis and Indegene, a healthcare solutions provider, among others, on the evolving role of MSLs and the potential value of hybrid models in this environment.